The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion
Abstract
Objective To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes. Research design and methods After completing a 4-week run-in period with BR, 146 adult patients with type 1 diabetes (with pretrial CSII experience) were randomly assigned (2:2:1) to CSII treatment with IAsp, BR, or lispro for 16 weeks in a multicenter, open-label, randomized, parallel-group study. Bolus insulin doses were administered 30 min before meals (BR) or immediately before meals (IAsp or lispro). Results Treatment groups had similar baseline HbA(1c) (7.3% +/- 0.7 for IAsp, 7.5% +/- 0.8 for BR, and 7.3% +/- 0.7 for lispro). After 16 weeks of treatment, HbA1c values were relatively unchanged from baseline, and the mean changes in baseline HbA1c values were not significantly different between the three groups (0.00 +/- 0.51, 0.15 +/- 0.63, and 0.18 +/- 0.84 for the IAsp, BR, and lispro groups, respectively). The rates of hypoglycemic episodes (blood glucose Conclusions Insulin aspart in CSII was as efficacious and well tolerated as BR and lispro and is a suitable insulin for continuous subcutaneous insulin infusion using external pumps.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one of the earliest studies of the frequency of insulin pump occlusion, reported in 2001, over a 24-week period, approximately 66% (38 of 58) subjects with type 1 diabetes using an insulin pump had an episode of hyperglycemia and 36% of the episodes were caused by an occlusion of the IIS.”
From Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block (2017) · cites this paper as [6]
In the citing paper
“There was no significant difference in the occlusion rate when these patients used either insulin lispro (LIS) or buffered regular insulin (BRI).6”
From Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block (2017) · cites this paper as [6]
In the citing paper
“In one of the earliest studies of the frequency of insulin pump occlusion, reported in 2001, over a 24-week period, approximately 66% (38 of 58) subjects with type 1 diabetes using an insulin pump had an episode of hyperglycemia and 36% of the episodes were caused by an occlusion of the IIS.”
From Insulin Pump Occlusions: For Patients Who Have Been Around the (Infusion) Block (2017) · cites this paper as [6]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Borch‐Johnsen, K., Neil, A., Balkau, B., Larsen, S. H., Nissinen, A. E. T., Pekkanen, J., Keinanen-Kiukaanniemi, S. M., Hiltunen, L. A., Kivelä, S., Tuomilehto, J. O., et al. (1999) · The Lancet · Cited by 1,272
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T., & Sekikawa, A. (1999) · Diabetes Care · doi:10.2337/diacare.22.6.920 · Cited by 1,165
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Balkau, B., Shipley, M. J., Jarrett, R. J., Pyörälà, K., Pyörälä, M., Forhan, A., & Eschwège, É. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 597
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Barrett-Connor, E., & Ferrara, A. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1236 · Cited by 369
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 285
Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Self-citation
Cited by
Sorted by citations
Items 101–148 of 148
Actualización del tratamiento farmacológico de la diabetes mellitus tipo 2.
González, E. D. O., Pérez, M. C., & Gumpert, S. A. (2008) · Cited by 4
Bramlage, P., Tittel, S. R., Müther, S., Reinhart-Steininger, B., Haberland, H., Khodaverdi, S., Zimny, S., Ohlenschläger, U., Lanzinger, S., & Haak, T. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01939-3 · Cited by 3
Kapur, R., Mittra, S., Tonpe, G., Adithi, P., Raj, P., Gudat, U., & Athalye, S. N. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2371046 · Cited by 3
Vaquero, P. M., Martínez, A. F., & Pallardo, L. F. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)74400-0 · Cited by 3
Use of new insulins in children
Regan, F. M., & Dunger, D. B. (2006) · Archives of Disease in Childhood Education & Practice · doi:10.1136/adc.2005.078188 · Cited by 3
Insulin Regimens for Type 1 Diabetes
Shah, B. R., & Zinman, B. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-310-1_10 · Cited by 3
van Laar, A., Gallardo‐Nuell, L., Pazmiño, S., Visser, M. M., Mertens, A. C., Vangoitsenhoven, R., Gillard, P., Al‐Ozairi, E., le Roux, C. W., Rosen, J., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103589 · Cited by 4
Chawla, M. S., Chawla, P., Saboo, B., Chawla, R., Gangopadhyay, K. K., Kalra, S., Aravind, S. R., Sinha, B., Shah, T. U., Kesavadev, J., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102587 · Cited by 2
Pharmacotherapy in Type 1 Diabetes
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.011 · Cited by 2
Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes Mellitus
Russell, A. W., Prins, J. B., & Martin, J. H. (2011) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000106 · Cited by 1
Management of Diabetes Mellitus with Insulin Lispro
Tanaka, M., & Itoh, H. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s1155 · Cited by 2
Nuevos abordajes terapéuticos de la diabetes mellitus tipo 1
Acosta, D. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74617-3 · Cited by 2
Lin, C.-H., Hsieh, F.-J., Van, Y.-H., & Lo, F. (2015) · BioMed Research International · doi:10.1155/2015/250656 · Cited by 1
Genetically engineered insulin and its pharmaceutical analogues
Гусаров, Д. А., Gusarova, V. D., Bayramashvili, D. I., & Миронов, А. Ф. (2008) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750808040057 · Cited by 1
Marcus, A. O. (2013) · The Open Diabetes Journal · doi:10.2174/1876524620130905001 · Cited by 1
Henrichs, H. R. (2010) · Der Diabetologe · doi:10.1007/s11428-008-0279-7 · Cited by 1
Zelinska, N. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-4-39 · Cited by 1
Insulin, glucagon, and hypoglycemic drugs
Krans, H. M. J. (2003) · Side effects of drugs annual · doi:10.1016/s0378-6080(03)80049-1 · Cited by 1
Comments On the Aace/Ace Statement on Glycemic Control for Patients With Type 2 Diabetes Mellitus
Eledrisi, M. S., Rodbard, H. W., Jellinger, P. S., Palma, M. J. D. C., Hernández, F. J. G., Román, J. S., Mariash, C. N., Shaw, S. J., & Bughi, S. (2010) · Endocrine Practice · doi:10.4158/ep.16.1.130 · Cited by 1
Continuous Subcutaneous Insulin Infusion in Childhood and Adolescence
Phillip, M., Weintrob, N., & Shalitin, S. (2005) · KARGER eBooks · doi:10.1159/000085796
CSIIにおける超速効型インスリン（インスリンアスパルト）の有用性についての検討
洋一, 今., 高根, 直., 修介, 香., 小路, 眞., 広松, 雄., & 研太郎, 山. (2008) · Tōnyōbyō/Tounyoubyou · doi:10.11213/tonyobyo.51.1
Facteurs prédictifs d’amélioration glycémique chez les patients diabétiques sous pompe à insuline
Saatdjian-Salino, L. (2013) · HAL
Humaninsulin oder Analoga in der Insulintherapie
Pfohl, M. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1149-5
Gregory, J. M. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_13
Insulin aspart: rapid control for postmeal glucose excursions
Christiansen, J. S. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.5.587
Insulina aspart en terapia con perfusión subcutánea continua de insulina
Castellanos, R. B., & Frías, M. M. (2012) · Avances en Diabetología · doi:10.1016/s1134-3230(12)70019-4
Ampudia‐Blasco, F. J. (2012) · Avances en Diabetología · doi:10.1016/s1134-3230(12)70018-2
Bloomgarden, Z. T. (2010) · Endocrine Practice · doi:10.4158/ep.16.s2.1
The use of ultra-short acting insulin preparations for insulin pumps
Андрианова, Е. А. (2012) · Problems of Endocrinology · doi:10.14341/probl201258346-50
Roe, E. D., Woo, J. S., & Raskin, P. (2012) · Diabetes Management · doi:10.2217/dmt.12.49
Self-citationPharmacothérapie du diabète de type 1
McGibbon, A., Richardson, C., Hernandez, C. A., & Dornan, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.005 · Cited by 1
Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes
Russell, A. W., Prins, J. B., & Martin, J. H. (2011)
Cander, S., Gül, Ö. Ö., & Tuncel, E. (2015) · Endocrinology research and practice. · doi:10.4274/tjem.2635
Investigation of Usability of MirioPen in Patients with Type 2 Diabetes Mellitus
Okada, M., 細江慎吾, Yamada, T., Yanbe, Y., Kato, Y., Nishikami, J., Okamoto, H., & Amioka, K. (2010) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.36.689
Pratoomsoot, C., Smith, H. T., Kalsekar, A., Boye, K. S., Pérez-Arellano, J.-L., & Valentine, W. J. (2009)
Çetinkalp, Ş., Erdoğan, M., Karadeniz, M., özbey, Y., Yılmaz, C., Tüzün, M., & Kabalak, T. (2007) · DOAJ (DOAJ: Directory of Open Access Journals)
Biester, T., & Wizemann, E. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-100389
Heise, T., & Biester, T. (2017) · Diabetologie und Stoffwechsel · doi:10.1055/s-0043-116018
Moderne Therapie des Typ-1-Diabetes – Pumpentherapie mit Insulinanaloga
Wizemann, E., & Biester, T. (2018) · Diabetes aktuell · doi:10.1055/a-0618-4826
Malignancy Concerns With Antidiabetic Therapies: Examining the Evidence
Lebovitz, H. E. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42872-1
(2006) · Wiley eBooks · doi:10.1002/9780470041000.cedt028
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00898-2
Pharmacothérapie du diabète de type 1
(2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.03.413
INSULINS AND OTHER HYPOGLYCEMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53271-8.50008-9
Gysling, E. (2005) · pharma-kritik · doi:10.37667/pk.2004.109
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00991-8
Ramirez, L. E. O., Ibáñez, D. F. Á., Morales, C. C. A., Arango, L. K. O., Plazas, M., & Escobar, I. D. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2024.101073
Guo, Y., Mei, Y., Bongaerts, B. W. C., Metzendorf, M., Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., et al. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012161.pub2
Metadata
- Authors
- Bode, B., Weinstein, R., Bell, D., McGill, J., Nadeau, D., Raskin, P., Davidson, J., Henry, R., Huang, W.-C., & Reinhardt, R. R.
- Affiliations
- Atlanta Diabetes Associates (US)
- Diablo Clinical Research (US)
- Kirklin Clinic (US)
- Washington University in St. Louis (US)
- Eastern Maine Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Endocrine & Diabetes Associates, Dallas, Texas
- VA San Diego Healthcare System (US)
- Novo Nordisk Pharmaceuticals, Princeton, New Jersey
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2002-03-01
- Volume
- 25
- Issue
- 3
- Pages
- 439-444
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2091336973
- Cited by
- 148
- References
- 26
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2020: 3 · 2018: 5 · 2017: 6 · 2016: 1 · 2015: 7 · 2014: 6 · 2013: 10 · 2012: 6
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- insulin aspart, insulin lispro, insulin pump therapy, type 1 diabetes, bolus insulin, glycemic control, HbA1c, hypoglycemia, insulin analogues
- MeSH terms
- Adult, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Safety, Body Mass Index, Insulin Aspart, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
